Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition containing calcium agonist and phenoxy acid compound

A technology of calcium antagonists and phenoxy acids, which is applied in the field of pharmacy, can solve the problems of preventing or treating hypertension combined with hyperlipidemia, and achieve the effects of delaying cardiovascular and cerebrovascular diseases, preventing or delaying damage, and taking medicine conveniently

Active Publication Date: 2007-01-10
SHENZHEN AUSA PHARM CO LTD +2
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In order to solve the clinical problem of lack of effective drugs for the prevention or treatment of hypertension combined with hyperlipidemia, the purpose of the present invention is to provide a pharmaceutical composition for the preparation of drugs for the prevention or treatment of hypertension combined with hyperlipidemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1. Effects of a pharmaceutical composition containing amlodipine and fenofibrate on blood pressure and blood lipids in hypertensive rats with hyperlipidemia

[0032] The left renal artery of SD rats was narrowed with a 0.2 mm silver clip, and the blood pressure of the rats increased by more than 150 mmHg after 8 to 10 weeks, and they were considered hypertensive animals. Another 20 normal rats were used as the normal control group. Feed high-fat feed to hypertensive rats (the formula is: cholesterol 1%, propylthiouracil 0.2%, sodium cholate 0.3%, lard 10%, basal feed 88.5%), normal control group rats are fed with common feed. After 4 weeks, blood pressure (systolic blood pressure SBP, diastolic blood pressure DBP) of the rats was measured, and blood samples were collected to measure serum cholesterol (CHO), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Low-density lipoprotein (VLDL). According to blood pressure and blood...

Embodiment 2

[0042] Example 2. Effect of a pharmaceutical composition containing nitrendipine and ciprofibrate on hypertensive rats with hyperlipidemia

[0043] The left renal artery of SD rats was narrowed with a 0.2 mm silver clip, and the blood pressure of the rats increased by more than 150 mmHg after 8 to 10 weeks, and they were considered hypertensive animals. Another 20 normal rats were used as the normal control group. Feed high-fat feed to hypertensive rats (the formula is: cholesterol 1%, propylthiouracil 0.2%, sodium cholate 0.3%, lard 10%, basal feed 88.5%), normal control group rats are fed with common feed. After 4 weeks, the blood pressure (SBP, DBP) of the rats was measured, and blood was collected to measure serum CHO, TG, HDL, LDL, and VLDL. According to blood pressure and blood lipid levels (mainly DBP, TG, VLDL), hypertensive rats with hyperlipidemia were divided into model group, nitrendipine group (1.0 mg / kg), ciprofibrate group (2.0 mg / kg), Nitrendipine+ciprofibrat...

Embodiment 3

[0056] Example 3. Effects of a pharmaceutical composition containing felodipine and benzclofibrate on blood pressure and blood lipids in hypertensive rats with hyperlipidemia

[0057] The left renal artery of SD rats was narrowed with a 0.2mm silver clip, and the blood pressure of the rats increased by more than 140mmHg after 8 to 10 weeks, and they were considered hypertensive animals. Another 20 normal rats were used as the normal control group. Feed high-fat feed to hypertensive rats (the formula is: cholesterol 1%, propylthiouracil 0.2%, sodium cholate 0.3%, lard 10%, basal feed 88.5%), normal control group rats are fed with common feed. After 4 weeks, the blood pressure (SBP, DBP) of the rats was measured, and blood was collected to measure serum CHO, TG, HDL, LDL, and VLDL. According to blood pressure and blood lipid levels (mainly DBP, TG, VLDL), hypertensive rats were divided into model group, felodipine group (1.0mg / kg), benzclofibrate group (10mg / kg), felodipine+ B...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses an application of medicine composition containing medicinal dose calcium antagonist, medicinal dose phenoxy acid medicine and pharmaceutically-acceptable carrier in the preparation of medicine with synergistic action of reducing blood pressure or / and synergistic action of reducing blood lipid or / and synergistic action of changing vascular compliance or / and synergistic action of delaying targent organ damage. Said invention also relates to the application of said medicine composition in preparation of medicine for preventing, curing and delaying angiocardiopathy and cerebrovascular diseases.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing a calcium antagonist and a phenoxy acid compound used in the preparation of drugs for lowering blood pressure, or / and lowering blood lipids, or / and changing the compliance of blood vessels, or / and delaying target organ damage in the application. The present invention belongs to the field of pharmacy. Background technique [0002] Cardiovascular disease is a common disease and accounts for the first cause of human death; epidemiological studies have found that most patients have high blood pressure and high blood lipids at the same time, and their risk of cardiovascular disease is very high. It is estimated that 30 million American patients have been diagnosed with these two high-risk factors; in China, a cross-sectional survey of 711 hypertensive patients with hyperlipidemia found that 186 hypertensive patients with hyperlipidemia, the disease The rate is 26.2%, which is signifi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/4422A61K9/16A61K9/20A61K9/48A61P9/12A61P9/10A61P3/06
Inventor 陈光亮王琳琳段炎炎李莉
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com